Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Active Biotech AB ( (SE:ACTI) ) is now available.
Active Biotech AB has announced a fully secured rights issue to raise approximately SEK 70 million, aimed at funding ongoing studies of tasquinimod in myelofibrosis and the development of laquinimod for inflammatory eye diseases. This financial move is expected to support the company’s strategic focus on advancing its clinical trials and business development activities, potentially enhancing its position in the biotech industry by addressing diseases with high unmet medical needs.
More about Active Biotech AB
Active Biotech is a Swedish biotech company focused on developing innovative immunomodulatory therapies for diseases with high unmet medical need, particularly in hematological malignancies and inflammatory eye diseases. The company is advancing two key compounds, tasquinimod and laquinimod, which have shown promise in previous studies and are supported by extensive data and global patents.
YTD Price Performance: 44.44%
Average Trading Volume: 4,892,505
Technical Sentiment Signal: Sell
Current Market Cap: SEK192.6M
For an in-depth examination of ACTI stock, go to TipRanks’ Overview page.